This module uses fundamental data of FibroBiologics Common to approximate its Piotroski F score. FibroBiologics Common F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of FibroBiologics Common Stock. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about FibroBiologics Common financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out FibroBiologics Common Altman Z Score, FibroBiologics Common Correlation, FibroBiologics Common Valuation, as well as analyze FibroBiologics Common Alpha and Beta and FibroBiologics Common Hype Analysis.
FibroBiologics
The current Net Debt is estimated to decrease to about 2.2 M. The current Short and Long Term Debt is estimated to decrease to about 3.7 M.
At this time, it appears that FibroBiologics Common's Piotroski F Score is Frail. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
The critical factor to consider when applying the Piotroski F Score to FibroBiologics Common is to make sure FibroBiologics is not a subject of accounting manipulations and runs a healthy internal audit department. So, if FibroBiologics Common's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if FibroBiologics Common's financial numbers are properly reported.
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between FibroBiologics Common's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards FibroBiologics Common in a much-optimized way.
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.
Net Debt
2.24 Million
At this time, FibroBiologics Common's Net Debt is most likely to increase significantly in the upcoming years.
About FibroBiologics Common Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze FibroBiologics Common Stock's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of FibroBiologics Common using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of FibroBiologics Common Stock based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Additional Information and Resources on Investing in FibroBiologics Stock
When determining whether FibroBiologics Common is a strong investment it is important to analyze FibroBiologics Common's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact FibroBiologics Common's future performance. For an informed investment choice regarding FibroBiologics Stock, refer to the following important reports:
You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FibroBiologics Common. If investors know FibroBiologics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FibroBiologics Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of FibroBiologics Common is measured differently than its book value, which is the value of FibroBiologics that is recorded on the company's balance sheet. Investors also form their own opinion of FibroBiologics Common's value that differs from its market value or its book value, called intrinsic value, which is FibroBiologics Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FibroBiologics Common's market value can be influenced by many factors that don't directly affect FibroBiologics Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between FibroBiologics Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroBiologics Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FibroBiologics Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.